Steven Cohen Infla Rx N.V. Transaction History

Point72 Asset Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.25 - $2.75 $157,000 - $345,400	125,600 Added 6.03%	2,206,893 $3.6 Million
Q3 2023 Nov 14, 2023	BUY	$2.66 - $4.33 $448,303 - $729,756	168,535 Added 8.81%	2,081,293 $6.2 Million
Q2 2023 Aug 14, 2023	BUY	$2.05 - $6.1 $3.92 Million - $11.7 Million	1,912,758 New	1,912,758 $8.53 Million
Q2 2020 Aug 14, 2020	SELL	$4.59 - $8.96 $490,234 - $956,972	-106,805 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.65 - $6.08 $283,033 - $649,374	106,805 New	106,805 $408,000
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $495,453 - $8.36 Million	-161,913 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $3.4 Million - $5.31 Million	109,190 Added 207.1%	161,913 $6.12 Million
Q4 2018 Feb 14, 2019	BUY	$23.33 - $36.37 $1.23 Million - $1.92 Million	52,723 New	52,723 $1.92 Million

13.2M

5.2K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $61M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.